AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04202939 — intervention group
Intervention type: OTHER
Intervention: nutrition
Description: type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
Study NCT03474302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Aerobic, strength training, balance, flexibility
Study NCT03474302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Successful Aging
Description: Healthy aging education
Study NCT02024607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT02725944 — intervention group
Intervention type: DEVICE
Intervention: Implantation of ICRM
Description: All patients will be implanted with ICRM in order to detect an occult PAF.
Study NCT01797120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
Study NCT01797120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
Study NCT01797120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
Study NCT01797120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
Study NCT01919294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone undecanoate
Description: Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
Study NCT01014390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WallFlex Biliary RX Fully Covered Stent System
Description: Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
Study NCT03908021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analysis and 16S rRNA gene-based analysis
Description: microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
Study NCT02024607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02024607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT03765268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurectomy in inguinal hernia repair
Description: Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
Study NCT03765268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve sparing in inguinal hernia repair
Description: Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
Study NCT04170179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
Study NCT02024607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02024607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study NCT01644708 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self empowerment
Description: 1. Group meeting, introducing the method and the assessment tools~1. Self-empowerment,~2. Handing over the journal,~3. Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal.
Study NCT00205556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: on-line hemodiafiltration
Description: addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
Study NCT00205556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: low flux hemodialysis
Description: standard treatment
Study NCT02610374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Agrarian Diet
Description: A diet higher in carbohydrates and lower in fats and sugars
Study NCT03343223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing.
Study NCT04020848 — intervention group
Intervention type: OTHER
Intervention: Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.
Description: Review of past medical history; review of paroxysmal events; identification of presence of seizures \& epilepsy \& epilepsy classification; characterization of the non-paroxysmal features; degree of paroxysmal, non-paroxysmal disability indices; Vineland II adaptive behavior scales scoring; behavioral evaluation; presence of a genetic mutation; pharmacological treatments already used; AHC paroxysmal events assessement during the time of study; patient calendar for the follow up of events, for the follow up of epileptic seizures; whether, or not, there was occurrence of a serious or potentially life-threatening event (status epilepticus, apnea requiring intervention, or death) during time of study; growth and somatic complaints; further information concerning family history \& comorbidities; past instrumental \& biochemical investigations (ECG, cardiac ultrasound results if done as part of patient's follow-up); electroencephalogram; polysomnography; urine samples of melatonin ; pupillometry
Study NCT02610374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Western-type Diet
Description: A diet higher in fats and lower in carbohydrates
Study NCT04170179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT04170179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study NCT00829413 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue®
Description: SonoVue (2.4 mL)
Study NCT01058421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive physical therapy
Description: four week course of daily intensive physical therapy
Study NCT01058421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: four weeks of routine physical therapy
Study NCT04414501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Separation Anxiety
Description: Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
Study NCT00358826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: oral dosing, 1 time daily for 12 or 24 weeks
Study NCT04020848 — intervention group
Intervention type: OTHER
Intervention: The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire
Description: Sleep Disturbance Scale for Children ; Horne \& Ostberg Circadian Typology Questionnaire
Study NCT02709005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Monolaurin Vaginal Gel
Description: Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
Study NCT02709005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
Study NCT00358826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dosing, 1 time daily for 12 or 24 weeks
Study NCT02903056 — intervention group
Intervention type: OTHER
Intervention: Rett Syndrome
Description: Diagnosis of Rett Syndrome
Study NCT01110681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)
Study NCT03651674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECT treatment
Description: Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
Study NCT03651674 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Drug treatment
Description: Patients only have antipsychotic drugs
Study NCT04080024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SN132D
Description: Novel manganese-based macromolecular MRI contrast agent
Study NCT01560312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation (Symplicity® Catheter System™)
Description: 4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
Study NCT02618603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Study NCT02618603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study NCT01422408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide Cream
Description: Given topically
Study NCT01422408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive fluocinonide cream
Study NCT01422408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00960180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR1817
Study NCT00960180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00566683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diazemuls, pethidine
Description: 5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
Study NCT00566683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Alfentanil
Description: Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
Study NCT03633942 — intervention group
Intervention type: DEVICE
Intervention: LMA Supreme
Description: Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
Study NCT01496833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankura Branched/Fenestrated Stent Graft
Description: Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
Study NCT01846793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: 2.5 mg NX-1207 in 10 mL saline vehicle
Study NCT01896882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Study NCT00343928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids
Description: Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
Study NCT00703690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0767
Description: MK0767 2.5, 5, and 10 mg/day supplied as tablets
Study NCT00703690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: fenofibrate
Description: fenofibrate 200 mg supplied as capsules
Study NCT00703690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: matching placebo will be supplied as tablets/capsules.
Study NCT01417507 — intervention group
Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: Undergo neurocognitive assessment
Study NCT02971358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Standard radical prostatectomy with extended lymph node dissection is performed.
Study NCT03593824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cataract removal surgery for dense cataract
Description: Participants were born with dense bilateral cataracts (extreme adversity) will undergo surgery for bilateral cataract removal at an early age, mostly around 3 months of age.
Study NCT03593824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cataract removal surgery for non-dense nuclear cataract
Description: Participants were born with non-dense and nuclear bilateral cataracts (watered-down adversity) will undergo cataract removal surgery bilaterally in a compromised timing, mostly around one year old.
Study NCT01417507 — intervention group
Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: Undergo MRI
Study NCT01417507 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01417507 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01417507 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02763514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 g PronovaPure 150:500 EE EU
Study NCT02763514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 g PronovaPure 500:200 EE EU
Study NCT02763514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3 g Placebo
Study NCT03138096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pb(PfCS@UIS4)-infected mosquitoes
Description: Pb(PfCS@UIS4)-infected mosquitoes
Study NCT01821625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
Study NCT02283996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf
Study NCT02283996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot Methylprednisolone
Description: 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
Study NCT03777592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
Study NCT03777592 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: erector spinae plane block
Description: local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
Study NCT00160732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic islet cells (human, U. Chicago)
Description: Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
Study NCT00160732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: Intraportal infusion of islet cell through the portal vein in the liver.
Study NCT00182455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25 - 400 mg/day x 12 weeks
Study NCT00182455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 - 400 mg/day x 12 weeks
Study NCT01916681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Foley & Misoprostol
Description: A cervical foley combined with misoprostol will be used to induce the patient.
Study NCT01916681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol Alone
Description: Misoprostol will be used alone to induce the patient
Study NCT01916681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Foley Alone
Description: A cervical foley alone will be used to induce the patient
Study NCT01916681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Foley & Pitocin
Description: A cervical foley combined with pitocin will be used to induce the patient
Study NCT04496193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
Study NCT04496193 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
Study NCT04496193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block
Description: Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
Study NCT03618173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
Study NCT03868449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question Prompt List
Description: Question prompt list
Study NCT03138096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge infection P. falciparum
Description: Challenge infection with bites of five infected Pf mosquitoes
Study NCT03138096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Challenge infection P. falciparum
Description: Challenge infection with bites of five infected Pf mosquitoes
Study NCT04274894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel 1.62%
Description: AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
Study NCT02044185 — intervention group
Intervention type: DRUG
Intervention: salvage chemotherapy, total body irradiation
Description: there are no direct interventions to our patients.
Study NCT03943784 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Variceal Ligation
Description: Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
Study NCT03618173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV saline serum at the dose of 0,2mL/kg maximum 8mL
Study NCT02371317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Patients are randomized to an intervention